2019 Confirmed Speakers
(by alphabetical order)
Abul K. Abbas, Andre Ballesteros-Tato, Christophe Benoist, Jeffrey Bluestone, Jen Bon Lui, Onur Boyman, Michael Farrar, Garrison Fathman, Jason Fontenot, Agnes Hartemann, Jens Humrich, David Klatzmann, John Koreth, Vijay Kuchroo, Claude Le Pen, Zhanguo Li, Loui Madakamutil, Thomas Malek, Encarnita Mariotti-Ferrandiz, Alexander Marson, Tewfik Miloud, Francisco Ramirez-Valle, Jerome Ritz, Michelle Rosenzwajg, Alberto Sanchez-Fueyo, Scott Snapper, Naomi Taylor, Nadia Tchao, Georges Tsokos, Harikesh Wong, Jonathan Zalevsky, Zinan Zhang
2022 Preliminary Agenda
Wed. 14
6.00 pm
Opening Sessions
Keynote lectures
Thu. 15
9.00 am
Session I
On mechanistic aspects
Fri. 16
9.00 am
Session IV.b
Lessons form current clinical trials with
plain IL-2
8.00 pm
Coffee Break
Coffee Break
Welcome reception
Session II
On mechanistic aspects
Session V
iMAP
Chair: C Benoist
Lunch & posters
Lunch & posters
2.30 pm
Session III
On mechanistic aspects
Coffee Break
Session IV.a
Lessons from current clinical trials with plain IL-2
2.30 pm
Session VI.a
Clinical trial results from Novel IL-2s
Coffee Break
Session VII
IL-2 in cancer therapy
6.30 pm
6.30 pm
Drinks & posters
Drinks & posters
7.30 pm
End of the day
7.30 pm
End of the day
Sat. 17
9.00 am
Session VIII
IL-2 and Treg cell therapies: competing or complementing?
Coffee Break
Session VI.b
Novel IL-2s in development
1.00 pm
Afterwords
2019 Schedule
Wed. 13
Thu. 14
8.45 am
Session I
On mechanistic aspects
Chair : T. Malek
Fri. 15
9.00 am
Session III
Lessons form current clinical trials with
plain IL-2
Chair : J.Koreth
Sat. 16
9.00 am
Session VII
IL-2 and Treg cell therapies: competing or complementing?
Chair : J. Fontenot
6.00 pm
Coffee Break
Session I
On mechanistic aspects
Chair : V. Kuchroo
Lunch Break
2.00 pm
Session II
Preclinical research and pharmacology
Chair : A. Abbas
Coffee Break
Session III
Lessons from current clinical trials with plain IL-2
Chair: G Tsokos
6.15 pm
Coffee Break
Session IV
From biomarkers to theranostics
Chair: C Benoist
Coffee Break
Session V
Novel IL-2s (Part II)
Chair: J. Mariau
Lunch Break
2.00 pm
Session V
Novel IL-2s (Part I)
Chair : D. Klatzmann
Coffee Break
Session VI
IL-2 in cancer therapy
Chair: J. Bluestone
12.30 pm
Afterwords
6.30 pm
Opening Session
Welcome words from Jean Chambaz and Martin Hirsch
Keynote Lecture
Chair: J. Bluestone
8.00 pm
Welcome party
Organizers
David
Klatzmann
iMAP coordinator
APHP, Sorbonne Université (SU), INSERM
Emmanuel
Gautherot
iMAP partner
Immunotech Beckman Coulter
Encarnita
Marriotti-Ferrandiz
iMAP partner
Sorbonne Université
Amélie
Bonnefond
iMAP partner
LIGAN
Emmanuelle
Lechatelier
iMAP partner
Metagenopolis
Lars
Jorgensen
iMAP partner
IHU-A-ICM
Dusko
Ehrlich
iMAP partner
Metagenopolis
Jeffrey
Lyons
Michelle Rosenzwajg
iMAP partner
AP-HP, SU, Inserm